Amarin Corporation plc (AMRN) Stock Score, Valuation & Financial Research
Amarin Corporation plc is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for AMRN
Amarin Corporation plc currently has a Wall Street Score of 23/100. The stored market price is $13.8. Its financial score is 39/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Amarin Corporation plc does
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active phar
AMRN financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $13.8
- Market capitalization:
- $285.4M
- Revenue:
- $186.2M
- Net income:
- $-27.1M
- Free cash flow:
- $6.7M
- Cash:
- $143.6M
- Total debt:
- $5.3M
- EPS:
- -1.43
- Financial score:
- 39/100
- Valuation score:
- 0/100
- Revenue score:
- 6/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $6.7M, showing positive cash generation.
- The balance sheet shows $143.6M of cash versus $5.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 39/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AMRN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.